Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03563040CT.gov Study of Photopheresis in the Treatment of Erythrodermic MF and SS | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mycosis Fungoides And Variants
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| VITPSO (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | P2 | CCC · 53 |
| Fludarabine | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BB |
| Romidepsin | Northwestern University | P2 | BB |
| Pembrolizumab | University of Michigan Rogel Cancer Center | P2 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Mogamulizumab | University of Michigan Rogel Cancer Center | P2 | B |
| Lenalidomide | Northwestern University | P2 | B |
| Lacutamab | Innate Pharma | P2 | B |
| Interferon Gamma-1B | National Cancer Institute (NCI) | P2 | B |
+20 more in the Mycosis Fungoides And Variants cohort
Other indications for VITPSO
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BB · 67 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 67 |
| Acquired Epidermolysis Bullosa | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FludarabineSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityBB
- RomidepsinNorthwestern UniversityBB
- PembrolizumabUniversity of Michigan Rogel Cancer CenterBB
- TacrolimusSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityB
- MogamulizumabUniversity of Michigan Rogel Cancer CenterB
Citation
Floatz Terminal. VITPSO in Mycosis Fungoides And Variants. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vitpso-mycosis-fungoides-and-variants
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →